Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Peptide Therapeutics Market – Insights

Peptides are selective and efficacious signaling molecules that bind to specific cell surface receptors to trigger intracellular effects.

The global peptide therapeutics market is estimated to account for US$ 23,319.3 Mn in terms of value and is expected to reach US$ 57,166.5 Mn by the end of 2027.

Global Peptide Therapeutics Market: Drivers

Increasing prevalence of metabolic diseases and cardiovascular disorders (CVDs) is expected to boost growth of the global peptide therapeutics market over the forecast period. For instance, according to American Heart Association’s Heart Disease and Stroke Statistics 2018, around 92.1 million adults in the U.S. are suffering from some form of CVD or the after-effects of stroke.

Moreover, increasing healthcare expenditure is also expected to aid in growth of the market. For instance, according to the Centers for Medicare & Medicaid Services (CMS), health spending in the U.S. is projected to grow at an average rate of 5.5% per year for 2018-27 and to reach nearly US$ 6.0 trillion by 2027.

North America region held dominant position in the global peptide therapeutics market in 2018, accounting for 42.1% share in terms of value, followed by Europe.

Peptide Therapeutics  | Coherent Market Insights

Global Peptide Therapeutics Market: Restraints

Poor chemical and physical stability and a short circulating plasma half-life of naturally occurring peptides are expected to hinder growth of the global peptide therapeutics market.

Moreover, presence of stringent safety regulations is also restraining the market growth. Pharmaceuticals products such as peptide therapeutics require better regulatory framework as these treat multiple pathological conditions; by 2020, the regulatory framework is expected to be better.

Global Peptide Therapeutics Market: Opportunities

R&D of new peptides is expected to offer lucrative growth opportunities for players in the market. For instance, in December 2019, CohBar, Inc. announced new preclinical data that confirmed the therapeutic potential of a novel CohBar peptide in a preclinical model of Idiopathic Pulmonary Fibrosis (IPF).

Moreover, R&D in microbiome research is also expected to boost growth of the peptide therapeutics market. In January 2020, researchers from The Chaim Sheba Medical Center, Israel, reported that high fructose consumption induced metabolic changes and dysbiosis in rats and that metabolic changes are probably independent of a specific microbiome profile. 

Parenteral sub segment in the route of administration segment in global peptide therapeutics market was valued at US$ 16,416.8 Mn in 2018 and is expected to reach US$ 40,790.6 Mn by 2027 at a CAGR of 10.5% during the forecast period.

Market Trends/Key Takeaways

The market is witnessing increasing adoption of new platforms that develop next-generation protein or peptide therapeutics. For instance, in January 2020, Xenetic Biosciences, Inc. announced publication of the data from the completed Phase 1/2 clinical study of SHP656 ("PSA-recombinant Factor VIII", "PSA-rFVIII") in the journal Haemophilia. The study used Xenetic's PolyXen technology – a patent-protected platform technology for creating next-generation protein or peptide therapeutics.

The market is also witnessing increasing M&A activities. For instance, in January 2020, Almirall, S.A. acquired Bioniz Therapeutics Inc., a clinical stage biopharmaceutical company that develops first-in-class peptide treatments for immuno-inflammatory diseases.

Regulations

U.S.

  • As per the FDC and PHS act of the U.S. FDA, CDER and CBER are responsible for certain part of therapeutic proteins
  • CDER now has regulatory role, which includes premarket review and continuing oversight of therapeutic peptides
  • 2012: As per FDA, ‘peptides are defined as any alpha amino acid polymer with specific defined sequence that is 40 amino acids or less in size’.
  • Since there are various peptide conjugate candidates that contain peptides in combination with small molecules, the regulatory aspect for peptide is still evolving
  • The FDA takes into account the history and manufacturing aspect of the candidate molecule to decide its regulatory pathway Example whether BLA would be submitted or NDA needs to be applied
  • All the non-clinical studies are carried out as per ICH-S6 guidelines

Peptide Therapeutics  | Coherent Market Insights

Global Peptide Therapeutics Market: Competitive Landscape

Major players operating in the global peptide therapeutics market include, AstraZeneca plc., Bachem Holding AG, CordenPharma International, Eli Lilly and Company, Ipsen S.A, Merck & Co., Inc., Novo Nordisk A/S, PolyPeptide Group, and Teva Pharmaceutical Industries Ltd.

Global Peptide Therapeutics Market: Key Developments

Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in October 2019, PolyPeptide Group collaborated with the Green Chemistry and Enabling Technologies Team of IBMM (Institut des Biomolécules Max Mousseron), for R&D greener solutions to produce synthetic peptides.

Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in July 2019, Xenetic Biosciences, Inc. completed acquisition of the novel CAR T (“Chimeric Antigen Receptor T Cell”) platform technology, called “XCART,” designed to use screening technique to identify peptide ligands that bind specifically to the unique B-cell receptor of malignant tumor cells.

Peptide therapeutics continue to expands its application by broaden molecular diversity and by engineering enhanced pharmaceutical properties. Research continues to expand the potential range of peptide-based pharmaceuticals to focus on treatment targets. However, large number of peptide targets shown in its early-stage of clinical trials or in preclinical models of disease, such as a melanocortin 4 receptor (MC4R) agonist, may reduce the body weight of patients with genetic obesity syndromes.

Furthermore, increasing development are in progress to extend the half-life period of peptide drugs; to improve the oral bioavailability of peptide therapeutics and to enhance the Central Nervous System (CNS) availability of peptide drugs through nanoparticle delivery in the indications such as Alzheimer’s disease and stroke.

Market Dynamics

Market players are engaged in developing novel and innovative peptide therapeutics drugs in order to offer tailored solution to target patient by increasing biocompatibility and potent therapeutic effects. Increasing prevalence of cancer and diabetes mellitus is projected to drive growth of the peptide therapeutics market over the forecast period. Also, clinical development in the field of peptide reflects it as an effective tool for molecular pharmacology.

Key features of the study:

  • This report provides in-depth analysis of peptide therapeutics in medical sector and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global peptide therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Takeda Pharmaceuticals Co. Ltd., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Encycle Therapeutics, Inc., CirclePharma, Inc., Pfizer Inc., Novartis AG, PeptiDream Inc., Amgen Inc., among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion and marketing tactics
  • The global peptide therapeutics market report caters to various stakeholders in this industry including investors, suppliers, peptide therapeutics based product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the peptide therapeutics market.

Detailed Segmentation:

  • Global Peptide Therapeutics Market, By Type:
    • Branded Peptide
    • Generic Peptide
  • Global Peptide Therapeutics Market, By Application:
    • Cancer
    • Cardiovascular Disease
    • Metabolic Disease
    • Respiratory Disease
    • Infectious Disease
    • Others
  • Global Peptide Therapeutics Market, By Route of Administration:
    • Oral Administration
    • Parenteral Administration
    • Others
  • Global Peptide Therapeutics Market, By Geography:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Type:
        • Branded Peptide
        • Generic Peptide
      • By Application
        • Cancer
        • Cardiovascular Disease
        • Metabolic Disease
        • Respiratory Disease
        • Infectious Disease
        • Others
      • By Route of Administration:
        • Oral Administration
        • Parenteral Administration
        • Others
    • Europe
      • By Country:
        • Germany
        • France
        • Italy
        • UK
        • Spain
        • Russia
        • Rest of Europe
      • By Type:
        • Branded Peptide
        • Generic Peptide
      • By Application
        • Cancer
        • Cardiovascular Disease
        • Metabolic Disease
        • Respiratory Disease
        • Infectious Disease
        • Others
      • By Route of Administration:
        • Oral Administration
        • Parenteral Administration
        • Others
    • Asia Pacific
      • By Country:
        • China
        • India
        • Japan
        • South Korea
        • Australia
        • Rest of Asia Pacific
      • By Type:
        • Branded Peptide
        • Generic Peptide
      • By Application
        • Cancer
        • Cardiovascular Disease
        • Metabolic Disease
        • Respiratory Disease
        • Infectious Disease
        • Others
      • By Route of Administration:
        • Oral Administration
        • Parenteral Administration
        • Others
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Type:
        • Branded Peptide
        • Generic Peptide
      • By Application
        • Cancer
        • Cardiovascular Disease
        • Metabolic Disease
        • Respiratory Disease
        • Infectious Disease
        • Others
      • By Route of Administration:
        • Oral Administration
        • Parenteral Administration
        • Others
    • Latin America
      • By Country:
        • Brazil
        • Argentina
        • Mexico
        • Rest of Latin America
      • By Type:
        • Branded Peptide
        • Generic Peptide
      • By Application
        • Cancer
        • Cardiovascular Disease
        • Metabolic Disease
        • Respiratory Disease
        • Infectious Disease
        • Others
      • By Route of Administration:
        • Oral Administration
        • Parenteral Administration
        • Others
    • Africa
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
      • By Type:
        • Branded Peptide
        • Generic Peptide
      • By Application
        • Cancer
        • Cardiovascular Disease
        • Metabolic Disease
        • Respiratory Disease
        • Infectious Disease
        • Others
      • By Route of Administration:
        • Oral Administration
        • Parenteral Administration
        • Others
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.*
      • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments
        • Strategies
      • Takeda Pharmaceuticals Co. Ltd.
      • Novo Nordisk A/S
      • Eli Lilly and Company
      • Sanofi S.A.
      • Encycle Therapeutics, Inc.
      • CirclePharma, Inc.
      • Pfizer Inc.
      • Novartis AG
      • PeptiDream Inc.
      • Amgen Inc.

*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet By Type
      • Market Snippet By Application
      • Market Snippet By Route of Administration
      • Market Snippet By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Regulatory Scenario
    • Market Trends
    • Epidemiology
    • Merger and Acquisitions
    • New Product Approvals/Launch
    • Pipeline Analysis
    • PEST Analysis
  4. Global Peptide Therapeutics Market, By Type, 2016 - 2026 (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-O-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Branded Peptide
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 – 2026, (US$ Million)
    • Generic Peptide
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 – 2026, (US$ Million)
  5. Global Peptide Therapeutics Market, By Application, 2016 - 2026 (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-O-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Cancer
      • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-O-Y Growth Analysis, 2017 - 2026
    • Cardiovascular Disease
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 – 2026, (US$ Million)
    • Metabolic Disease
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 – 2026, (US$ Million)
    • Respiratory Disease
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 – 2026, (US$ Million)
    • Infectious Disease
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 – 2026, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 – 2026, (US$ Million)
  6. Global Peptide Therapeutics Market, By Route of Administration, 2016 - 2026 (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-O-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Oral Administration
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 – 2026, (US$ Million)
    • Parenteral Administration
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 – 2026, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 – 2026, (US$ Million)
  7. Global Peptide Therapeutics Market, By Regions, 2016 - 2026 (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-O-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • North America
      • Market Size and Forecast, By Type, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Application, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Type, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Application, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Type, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Application, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Type, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Application, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Type, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Application, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • Northern Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Type, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Application, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Takeda Pharmaceuticals Co. Ltd.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      •  Novo Nordisk A/S 
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Encycle Therapeutics, Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • CirclePharma, Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Novartis AG
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • PeptiDream Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Amgen Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Analyst Views
    • Research Methodology
    • About Us and Sales Contact

*Browse 26 market data tables and 45 figures on "Peptide Therapeutics Market - Global forecast to 2026”.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner